REPLIGEN CORP 8K

Repligen Corporation entered into a definitive, mostly stock-and-cash agreement to acquire BioLife Solutions, Inc. for an enterprise value of about $1.5 billion, expecting the deal to close in Q4 2026 and be accretive to growth and earnings while expanding its cell therapy offerings.

Repligen Corporation announced that it has entered into a definitive agreement to acquire BioLife Solutions, Inc. for a total enterprise value of approximately $1.5 billion, with BioLife stockholders to receive $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share (valued at $31.00 per share), subject to regulatory and BioLife stockholder approvals and expected to close in the fourth quarter of 2026; the transaction, approved unanimously by both boards, is structured as approximately 64% stock and 36% cash, is anticipated to be immediately accretive to Repligen’s top-line growth, adjusted margins, and adjusted EPS (by at least $0.05 in year one and $0.25 in year two), includes expected cost synergies of at least $20 million in year one and $30 million in year two, and is intended to expand Repligen’s cell therapy capabilities by adding BioLife’s market‑leading biopreservation media and related cell processing tools, alongside preliminary, unaudited second quarter 2026 revenue updates for both companies.

Filing Facts

CIK

730272

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-311402

Alert Tier

8